Acetic Acid

Acetic Acid

SCHEMBL3028566

CC(=O)O.CC(=O)O.CC(=O)O.CCCCCCCCC(=O)OCC

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 1/20 0.52
DGKA P23743 1/20 0.67
PAM P19021 2/20 0.66
TSHR P16473 4/20 0.56
MAPT P10636 1/20 0.56
CYP1A2 P05177 1/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
DNM1 Q05193 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
DUSP3 P51452 1/20 0.53
PPARG P37231 4/20 0.52
PPARD Q03181 4/20 0.52
PPARA Q07869 4/20 0.52
GPR84 Q9NQS5 3/20 0.52
HDAC11 Q96DB2 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
SLC22A6 Q4U2R8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL6448229 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL989180 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL5395399 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Ethyl Tetradecanoate SCHEMBL8330964 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL1682182 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL173634 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL2213929 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL787652 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL543614 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2
Acetic Acid SCHEMBL8469053 1.00 DGKA (0.67) DGKAPAMTSHRMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101107227-B 5-aminoindole derivatives HOFFMANN LA ROCHE 2010-09-22 CN disclosed
US-7754736-B2 5-aminoindole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. (US) 2010-07-13 US disclosed
EP-1611104-B1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-07-01 EP disclosed
US-20090069311-A1 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS NETTEKOVEN MATTHIAS HEINRICH 2009-03-12 US disclosed
US-7456174-B2 5-aminoindole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. (US) 2008-11-25 US disclosed
CN-100432056-C Tetrahydroisoquinolinylacetamide derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD (CH) 2008-11-12 CN disclosed
CN-101107227-A 5-aminoindole derivatives HOFFMANN LA ROCHE (CH) 2008-01-16 CN disclosed
US-20060178515-A1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists ACTELION PHARMACEUTICALS, LTD. (CH) 2006-08-10 US disclosed
US-20060160855-A1 5-Aminoindole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
CN-1764647-A Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD (CH) 2006-04-26 CN disclosed
EP-1611104-A1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2006-01-04 EP disclosed
WO-2004085403-A1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2004-10-07 WO disclosed
EP-0886647-B1 SERINE PROTEASE INHIBITORS AKZO NOBEL NV (NL) 2002-07-24 EP disclosed
US-6410684-B1 ENZYME INHIBITOR FOR USE IN THE TREATMENT OF THROMBOSIS AKZO NOBEL N.V. (NL) 2002-06-25 US disclosed
CN-1212704-A Serine protease inhibitors AKZO NOBEL NV (NL) 1999-03-31 CN disclosed
EP-0886647-A1 SERINE PROTEASE INHIBITORS Akzo Nobel N.V. (NL) 1998-12-30 EP disclosed
WO-1997031937-A1 SERINE PROTEASE INHIBITORS AKZO NOBEL N.V. (NL) 1997-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069311-A1 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS HRH3, HTR5A, HRH4 ESR1 566/4885DGKA 4083/4885PAM 909/4885
US-20060178515-A1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists HCRTR2, HCRTR1, OXTR ESR1 1410/4885DGKA 2612/4885PAM 956/4885
US-20060160855-A1 5-Aminoindole derivatives as H3 inverse agonists HRH3, HTR5A, HRH4 ESR1 566/4885DGKA 4083/4885PAM 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.